Search Results - retinoblastoma

2 Results

Sort By:

Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma

Abstract: Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed....

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Carol Thiele Galetto, Nan Li, Rosa Nguyen, Rosandra Kaplan

Keywords(s): CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers

Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming

Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing